

Lysosomal-specific Cholesterol Reduction by Biocleavable Polyrotaxanes for Ameliorating Niemann-Pick Type C Disease

Atsushi Tamura¹, and Nobuhiko Yui¹

¹ Department of Organic Biomaterials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan. Correspondence and requests for materials should be addressed to N.Y. (E-mail: yui.org@tmd.ac.jp)

Methods

Reagents. Pluronic P123, a triblock copolymer of poly(ethylene glycol) (PEG)-*b*-poly(propylene glycol) (PPG)-*b*-PEG, was obtained from Sigma-Aldrich (Milwaukee, WI, USA). The number of monomer repeating units in PEG and PPG segments were determined to be 25.2×2 ($M_{n,PEG}$: $1,100 \times 2$) and 71.5 ($M_{n,PPG}$: 4,150), respectively, by ¹H nuclear magnetic resonance (NMR) spectroscopy. β -Cyclodextrin (β -CD), acryloyl chloride, 2-aminoethanol, cystamine dihydrochloride, cysteamine hydrochloride, *N,N*-dimethylaminoethyl amine (DMAEA), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM), and triethylamine (TEA) were obtained from Wako Pure Chemical Industries (Osaka, Japan). Cystamine dihydrochloride was desalted just before use according to a previously described procedure^{S1}. Fluorescein isothiocyanate ethylenediamine (FITC-EDA) was synthesized according to a previously described procedure^{S2}. *N,N'*-Carbonyldiimidazole (CDI), heptakis(2,6-di-*O*-methyl)- β -cyclodextrin (DM- β -CD), (2-hydroxypropyl)- β -cyclodextrin (HP- β -CD, averaged molecular weight of 1,460), and *N*-(triphenylmethyl)glycine (Trt-Gly-OH) were obtained from Sigma-Aldrich. 3,9-Bis(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecane was obtained from TCI (Tokyo, Japan). Other solvents and reagents were obtained from Kanto Chemicals (Tokyo, Japan). The Milli-Q water used in this study was prepared using an ultrapure water purification system (Academic A10) (Millipore, Billerica, MA).

Characterization of polymers and polyrotaxanes. Size exclusion chromatography (SEC) was carried out on an HLC-8120 system (Tosoh, Tokyo, Japan) equipped with a combination of TSKgel α -4000 and α -2500 columns (Tosoh), eluted with dimethylsulfoxide (DMSO) containing 10 mM lithium bromide (LiBr) at a flow rate of 0.35 mL/min at 60 °C. The $M_{n,SEC}$ and M_w/M_n were

calculated from the calibration curve of PEG standard (Agilent Technologies, Wilmington, DE, USA). ^1H NMR spectra were recorded on a Bruker Avance III 500 MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany) in CDCl_3 or $\text{DMSO-}d_6$ (Sigma-Aldrich) at room temperature.

Synthesis of α,ω -biscarbonylimidazolyl Pluronic P123 (P123-CI). Pluronic P123 (20.0 g, 3.14 mmol) and CDI (19.8 g, 62.8 mmol) were loaded into a round-bottomed flask and dissolved in 270 mL of tetrahydrofuran (THF). The solution was stirred for 24 h at room temperature. After the reaction, the polymer was poured into diethyl ether to precipitate the polymer. This purification process was repeated three times to remove the unreacted reagents. Finally, the recovered polymer was dried under reduced pressure to obtain α,ω -biscarbonylimidazolyl Pluronic P123 (P123-CI) (19.75 g, 95.9% yield). ^1H NMR (500 MHz, CDCl_3) δ = 1.13 (m, 214H, CH_3 of PPG), 3.40 (m, 71H, $-\text{CH}_2\text{-CH-}$ of PPG), 3.54 (m, 142H, $-\text{CH}_2\text{-CH-}$ of PPG), 3.64 (m, 202H, $-\text{CH}_2\text{-CH}_2\text{-O-}$ of PEG), 4.56 (t, 4H, $-\text{CH}_2\text{-O-C(=O)-}$), 7.07 (m, 2H, $-\text{C(=O)-N-CH=CH-N-}$), 7.44 (m, 2H, $-\text{C(=O)-N-CH=CH-N-}$), 8.16 (s, 2H, $-\text{C(=O)-N-CH= N-}$).

Synthesis of α,ω -bisamino Pluronic P123 bearing disulfide linkers (P123-SS-NH₂). Desalted cystamine (2.02 g, 27.4 mmol) was loaded into a round-bottomed flask and dissolved in 72 mL of *N,N*-dimethylformamide (DMF). Then, P123-CI (9.0 g, 1.37 mmol) dissolved in 8 mL of DMF was added dropwise into the flask. The solution was stirred for 24 h at room temperature. After the reaction, the polymer was purified by dialysis against methanol for 3 days (Spectra/Por 6, molecular weight cut-off of 1,000) (Spectrum Laboratories). Finally, the solvent was removed under reduced pressure to obtain α,ω -bisamino Pluronic P123 bearing disulfide linkages (P123-SS-NH₂) (4.95 g, 53.3% yield). ^1H NMR (500 MHz, CDCl_3 , **Figure S2B**) δ = 1.16 (m, 214H, CH_3 of PPG), 2.69 (m, 4H, $-\text{O(=O)-NH-CH}_2\text{-CH}_2\text{-S-S-}$), 2.87 (t, 4H, $-\text{S-S-CH}_2\text{-CH}_2\text{-NH}_2$), 2.93 (t, 4H, $-\text{S-S-CH}_2\text{-CH}_2\text{-NH}_2$), 3.20 (t, 4H, $-\text{O(=O)-NH-CH}_2\text{-CH}_2\text{-S-S-}$), 3.40 (m, 71H, $-\text{CH}_2\text{-CH-}$ of PPG), 3.54 (m, 142H, $-\text{CH}_2\text{-CH-}$ of PPG), 3.64 (m, 202H, $-\text{CH}_2\text{-CH}_2\text{-O-}$ of PEG), 4.30 (t, 4H, $-\text{CH}_2\text{-O(=O)-NH-}$).

Synthesis of α,ω -bisamino Pluronic P123 (P123-NH₂). Ethylenediamine (1.65 g, 27.5 mmol) was loaded into a round-bottomed flask and dissolved in 72 mL of *N,N*-dimethylformamide (DMF). Then, α,ω -biscarbonylimidazole pluronic P123 (9.0 g, 1.37 mmol) dissolved in 8 mL of DMF was added dropwise into the flask. The solution was stirred for 24 h at room temperature. After the reaction, the polymer was purified by dialysis against methanol for 3 days (Spectra/Por 6, molecular weight cut-off of 1,000). Finally, the solvent was removed under reduced pressure to obtain α,ω -bisamino Pluronic P123 (P123-NH₂) (5.85 g, 65.2% yield). ^1H NMR (500 MHz, CDCl_3) δ =

1.16 (m, 214H, CH_3 of PPG), 3.40 (m, 71H, $-\text{CH}_2-\text{CH}-$ of PPG), 3.54 (m, 142H, $-\text{CH}_2-\text{CH}-$ of PPG), 3.64 (m, 202H, $-\text{CH}_2-\text{CH}_2-\text{O}-$ of PEG), 4.35 (t, 4H, $-\text{CH}_2-\text{O}(=\text{O})-\text{NH}-$).

Synthesis of α,ω -bisamino Pluronic P123 bearing cyclic acetal linkers (P123-ace- NH_2).

3,9-Bis(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecane (6.81 g, 24.8 mmol) was loaded into a round-bottomed flask and dissolved in 100 mL of *N,N*-dimethylformamide (DMF). Then, α,ω -biscarbonylimidazole pluronic P123 (8.14 g, 1.24 mmol) dissolved in 10 mL of DMF was added dropwise into the flask. The solution was stirred for 24 h at room temperature. After the reaction, the polymer was purified by dialysis against methanol for 3 days (Spectra/Por 6, molecular weight cut-off of 1,000). Finally, the solvent was removed under reduced pressure to obtain α,ω -bisamino Pluronic P123 bearing cyclic acetals (P123-ace- NH_2) (7.0 g, 80.9% yield). ^1H NMR (500 MHz, CDCl_3) δ = 1.16 (m, 214H, CH_3 of PPG), 1.57 (m, 4H, $-\text{CH}_2-\text{O}(=\text{O})-\text{NH}-\text{CH}_2-\text{CH}_2-$), 1.66 (m, 12H), 2.72 (t, 4H, $-\text{CH}_2-\text{NH}_2$), 3.20 (m, 4H, $-\text{CH}_2-\text{O}(=\text{O})-\text{NH}-\text{CH}_2-$), 3.31-3.60 (m, 229H, $-\text{CH}_2-\text{CH}-$ of PPG, $-\text{CH}_2-\text{CH}-$ of PPG, $-\text{O}-\text{CH}_2-\text{C}$), 3.64 (m, 202H, $-\text{CH}_2-\text{CH}_2-\text{O}-$ of PEG), 4.23 (t, 4H, $-\text{CH}_2-\text{O}(=\text{O})-\text{NH}-$), 4.49 (m, 4H, $-\text{O}-\text{CH}_2-\text{C}$), 4.55 (m, 4H, $-\text{CH}_2-\text{CH}-$), 4.92 (m, 2H, $-\text{O}-\text{CH}_2-\text{C}$).

Synthesis of α,ω -bisamino Pluronic P123 bearing ester linkers (P123-COO- NH_2).

The Pluronic P123 (10.0 g, 1.57 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 133 mL) under a nitrogen atmosphere. Then, TEA (3.3 mL, 23.5 mmol) and acryloyl chloride (1.28 mL, 15.7 mmol) were successively added to the flask at 0 °C, and the system was stirred for 24 h at room temperature. After the reaction, the polymer was purified by dialysis against methanol for 3 days (Spectra/Por 6, molecular weight cut-off of 1,000). Finally, the solvent was removed under reduced pressure to obtain α,ω -bisacryloyl P123 (P123-acrylate) (6.12 g, 60.2% yield). ^1H NMR (500 MHz, CDCl_3) δ = 1.13 (m, 214H, CH_3 of PPG), 3.40 (m, 71H, $-\text{CH}_2-\text{CH}-$ of PPG), 3.54 (m, 142H, $-\text{CH}_2-\text{CH}-$ of PPG), 3.64 (m, 202H, $-\text{CH}_2-\text{CH}_2-\text{O}-$ of PEG), 4.28 (t, 4H, $-\text{CH}_2-\text{O}-\text{CO}-$), 5.81 (dd, 2H, $-\text{CH}=\text{CH}_2$), 6.13 (dd, 2H, $-\text{CH}=\text{CH}_2$), 6.41 (dd, 2H, $-\text{CH}=\text{CH}_2$).

The P123-acrylate (5.0 g, 0.53 mmol) and cysteamine hydrochloride (1.2 g, 10.6 mmol) were loaded into a round-bottomed flask and dissolved in anhydrous *N,N*-dimethylformamide (DMF, 40 mL). The system was stirred for 24 h at room temperature. After the reaction, DMF was evaporated and diluted with water, and the polymer was purified by dialysis against methanol for 3 days (Spectra/Por 6, molecular weight cut-off of 1,000). Finally, the solvent was removed under reduced pressure to obtain α,ω -bisamino Pluronic P123 bearing ester linkages (P123-COO- NH_2). ^1H NMR (500 MHz, CDCl_3) δ = 1.10 (m, 214H, CH_3 of PPG), 2.69 (t, 4H, $-\text{CO}-\text{CH}_2-\text{CH}_2-\text{S}-$), 2.86 (t, 4H, $-\text{CO}-\text{CH}_2-\text{CH}_2-\text{S}-$), 2.93 (t, 4H, $-\text{CH}_2-\text{CH}_2-\text{NH}_3$), 3.18 (m, 4H, $-\text{CH}_2-\text{CH}_2-\text{NH}_3$), 3.40 (m, 71H, $-\text{CH}_2-\text{CH}-$ of PPG), 3.54 (m, 142H, $-\text{CH}_2-\text{CH}-$ of PPG), 3.64 (m, 202H, $-\text{CH}_2-\text{CH}_2-\text{O}-$ of PEG), 4.29 (t, 4H, $-\text{CH}_2-\text{O}-\text{CO}-$), 7.93 (m, 6H, $-\text{CH}_2-\text{CH}_2-\text{NH}_3$).

Synthesis of polyrotaxane. Typical procedure for the synthesis of PRX bearing disulfide linkages (SS-PRX) is as follows: first, a saturated solution of β -CD was prepared by dissolving β -CD (12.0 g, 10.57 mmol) in 600 mL of phosphate buffer saline (PBS) (Sigma). Then, P123-SS-NH₂ (1.0 g, 147 μ mol) dissolved in a small aliquot of water was added to the β -CD saturated solution, and the system was stirred for 24 h at room temperature, during which a white precipitate of pseudopolyrotaxane was obtained. After the reaction, the precipitate was collected by centrifugation (7,000 rpm, 10 min) and freeze-dried for 1 day to obtain pseudopolyrotaxane as a white powder. Then, Trt-Gly-OH (1.63 g, 5.14 mmol) and DMT-MM (1.63 g, 5.87 mmol) were dissolved in 56 mL of methanol/DMF (1/4 v/v), and this solution was added to the pseudopolyrotaxane. The resulting reaction mixture was stirred for 24 h at room temperature. After the reaction, the precipitate was collected by centrifugation (7,000 rpm, 10 min) and successively washed with DMF and water. This washing process was repeated four times to completely remove the free β -CD and unreacted reagents. The recovered PRX was freeze-dried to obtain SS-PRX (697.2 mg, 20.0% yield based on P123 mol%). The number of β -CDs threaded onto the P123 was determined from the ¹H NMR peak area between 4.84 ppm (H₁ proton of β -CD) and 1.06 ppm (-CH₃ of the P123 axle). ¹H NMR (500 MHz, DMSO-*d*₆) δ = 1.06 (m, -CH₃ of P123), 3.0-3.9 (m, -CH₂CH₂O- and -CH₂-CH- of P123 and H₂, H₃, H₄, H₅, and H₆ protons of β -CD), 4.44 ppm (m, OH₆ proton of β -CD), 4.84 ppm (m, H₁ proton of β -CD), 5.5-5.9 ppm (m, OH₂ and OH₃ protons of β -CD), 7.21 (t, Trt group), 7.32 (t, Trt group), 7.41 (d, Trt group).

Synthesis of hydroxyethyl group-modified polyrotaxane. The typical procedure for the synthesis of hydroxyethyl group-modified SS-PRX (HE-SS-PRX) is as follows: SS-PRX (250 mg, 11.2 μ mol) was dissolved in 10 mL of anhydrous DMSO. CDI (235 mg, 1.45 mmol) was added to this solution and stirred for 24 h at room temperature. Then, HEA (439 μ L, 7.25 mmol) was added to the reaction mixture and stirred for a further 24 h at room temperature. After the reaction, the PRX was purified by dialysis against methanol for 3 days (Spectra/Por 6, molecular weight cut-off of 3,500). The recovered solution was concentrated and diluted with water. This aqueous solution was lyophilized to obtain HE-SS-PRX as a white powder (231.5 mg, 76.8% yield). The number of modified HE groups on PRX was calculated by the ¹H NMR peak area between 3.04 ppm (-CH₂-CH₂-OH of HE group) and 4.9-5.5 ppm (H₁ proton of β -CD). The *M*_{n,NMR} of HE-SS-PRX was calculated based on the numbers of threaded CDs and HE groups. ¹H NMR (500 MHz, DMSO-*d*₆) δ = 1.06 (m, -CH₃ of P123), 3.04 ppm (-CH₂-CH₂-OH of HE group), 3.1-4.5 (m, -CH₂CH₂O- and -CH₂-CH- of P123 and H₂, H₃, H₄, H₅, and H₆ protons of β -CD), 4.63 ppm (m, OH₆ proton of β -CD), 4.84 (m, H₁ proton of β -CD), 5.5-5.9 ppm (m, OH₂ and OH₃ protons of β -CD), 7.00 (m, -O-CO-NH-CH₂-CH₂-OH of HE group) 7.22 (t, Trt group), 7.32 (t, Trt group), 7.42 (d, Trt group).

Synthesis of fluorescein isothiocyanate-labeled HE-SS-PRX (FITC-HE-SS-PRX)^{S3}. HE-SS-PRX (30 mg, 1.15 μmol) was dissolved in 3 mL of anhydrous DMSO. CDI (4.83 mg, 29.8 μmol) was added to this solution and stirred for 24 h at room temperature to activate the hydroxyl groups. Then, FITC-EDA (2.67 mg, 5.95 μmol) was added to the reaction mixture and stirred for a further 24 h at room temperature. After the reaction, the solution was purified by dialysis against water for 3 days (Spectra/Por 6, molecular weight cut-off of 3,500). Finally, the aqueous solution was lyophilized to obtain fluorescein-labeled HE-SS-PRX (FITC-HE-SS-PRX) (13.2 mg). The number of modified fluorescein molecules on PRX was determined by the absorbance of fluorescein at 494 nm, and approximately 0.52 fluorescein molecules were labeled on HE-SS-PRX (0.04 fluoresceins/ β -CD).

Synthesis of fluorescein isothiocyanate-labeled HP- β -CD (FITC-HP- β -CD). HP- β -CD (200 mg, 136 μmol) was dissolved in 10 mL of anhydrous DMSO. CDI (66.6 mg, 411 μmol) was added to this solution and stirred for 24 h at room temperature to activate the hydroxyl groups. Then, FITC-EDA (61.6 mg, 137 μmol) was added to the reaction mixture and stirred for an additional 24 h at room temperature. After the reaction, the solution was purified by dialysis against water for 10 days to completely remove unreacted FITC-EDA (Spectra/Por 6, molecular weight cut-off of 1,000). Finally, the aqueous solution was lyophilized to obtain fluorescein-labeled HP- β -CD (FITC-HP- β -CD) (16.9 mg). The number of modified fluorescein molecules on HP- β -CD was determined to be 0.83. Then, the FITC-HP- β -CD was mixed with non-labeled HP- β -CD to adjust the number of fluorescein molecules on β -CD with FITC-HE-SS-PRX (0.04 fluorescein/HP- β -CD).

References.

- S1. Alferiev, I. S., Connolly, J. M. & Levy, R. J. A novel mercapto-bisphosphonate as an efficient anticalcification agent for bioprosthetic tissues. *J. Organomet. Chem.* **690**, 2543–2547 (2005)
- S2. Nukolova, N. V., Oberoi, H. S., Cohen, S. M., Kabanov, A. V. & Bronich, T. K. Folate-decorated nanogels for targeted therapy of ovarian cancer. *Biomaterials* **32**, 5417–5426 (2011).
- S3. Tamura, A. & Yui, N. Cellular internalization and gene silencing of siRNA polyplexes by cytoleavable cationic polyrotaxanes with tailored rigid backbones. *Biomaterials* **34**, 2480–2491 (2013).



A**B**

Figure S1. (A) Preparation scheme of HE-SS-PRX, HE-ace-PRX, and non-degradable HE-PRX. (B) Preparation scheme of HE-COO-PRX.




Figure S2. (A) SEC charts of β -CD (a), P123-SS-NH₂ (b), SS-PRX (c), HE-SS-PRX (d) in DMSO at 60 °C. (B, C) ¹H NMR spectra of SS-PRX (B) and HE-SS-PRX (C) in DMSO-*d*₆.




Figure S3. Hemolysis of rat erythrocytes incubated with non-degradable HE-PRX (triangles) or degradable HE-SS-PRX (diamonds) at various β -CD concentrations in the presence (open symbols) or absence (closed symbols) of 5 mM glutathione (GSH) for 3 h at 37 °C. Data are expressed as the mean \pm S.D. (n = 3).

A

| sample code | Number of threaded β -CDs ^a | Number of HE groups ^a | $M_{n, NMR}$ ^b | EC_{50} (μ M) |
|-------------|--|----------------------------------|---------------------------|----------------------|
| HE-SS-PRX | 12.9 | 53.4 | 26,900 | 24.2 ± 2.3 |
| HE-COO-PRX | 11.7 | 65.9 | 26,500 | 48.6 ± 6.5 |
| HE-ace-PRX | 12.9 | 66.9 | 28,100 | 131.4 ± 59.9 |
| HE-PRX | 11.3 | 65.3 | 25,700 | > 10,000 |

^aDetermined by ¹H NMR in DMSO-d₆. ^bCalculated based on the chemical composition determined by ¹H NMR.




Figure S4. (A) Characterization of PRXs and their EC_{50} value in reducing accumulated cholesterols in NPC1 cells. (B) The amount of intracellular total cholesterol in NPC1 cells incubated with HE-SS-PRX, HE-COO-PRX, HE-ace-PRX, and non-degradable HE-PRX at various β -CD concentrations for 24 h at 37 °C. The dashed lines represent the amount of intracellular total cholesterol in non-treated normal and NPC1 cells. Data are expressed as the mean \pm S.D. (n = 3).

Table S1. The sequence of primer sets for real-time RT-PCR.

| Target gene | Forward | Reverse |
|---------------------------------|---|--|
| human SREBP-2 (NM_004599.3) | 5'-ACA ACC CAT AAT ATC ATT GAG AAA CG-3' | 5'-TTG TGC ATC TTG GCG TCT GT-3' |
| human HMGCR (NM_000859.2) | 5'-GCC TGG CTC GAA ACA TCT GAA-3' | 5'-CTG ACC TGG ACT GGA AAC GGA TA-3' |
| human HMGCS (NM_001098272.2) | 5'-GTA TGC CCT GGT AGT TGC AGG AG-3' | 5'-TGT TGC ATA TGT GTC CCA CGA A-3' |
| human LDLR (NM_000527.4) | 5'-CAA CGG CTC AGA CGA GCA AG-3' | 5'-AGT CAC AGA CGA ACT GCC GAG A-3' |
| human ACTB (NM_001101.3) | 5'-TGG CAC CCA GCA CAA TGA A-3' | 5'-CTA AGT CAT AGT CCG CCT AGA AGC A-3' |